Pearson JD - Search Results

1

Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force.

Cleeland CS, Sloan JA, Cella D, Chen C, Dueck AC, Janjan NA, Liepa AM, Mallick R, O'Mara A, Pearson JD, Torigoe Y, Wang XS, Williams LA, Woodruff JF; CPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force. Cleeland CS, et al. Among authors: pearson jd. Cancer. 2013 Jan 15;119(2):411-20. doi: 10.1002/cncr.27744. Epub 2012 Aug 28. Cancer. 2013. PMID: 22930243 Free article.

2

Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.

Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C, Cai B, Chawla SP, Grunberg SM. Martin AR, et al. Among authors: pearson jd. Eur J Cancer. 2003 Jul;39(10):1395-401. doi: 10.1016/s0959-8049(03)00299-5. Eur J Cancer. 2003. PMID: 12826042 Clinical Trial.

3

Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall.

Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Martin AR, et al. Among authors: pearson jd. Support Care Cancer. 2003 Aug;11(8):522-7. doi: 10.1007/s00520-003-0482-4. Epub 2003 Jun 25. Support Care Cancer. 2003. PMID: 12827483 Clinical Trial.

4

Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses.

Aubry A, Pearson JD, Charish J, Yu T, Sivak JM, Xirodimas DP, Avet-Loiseau H, Corre J, Monnier PP, Bremner R. Aubry A, et al. Among authors: pearson jd. Cell Rep. 2024 Feb 27;43(2):113711. doi: 10.1016/j.celrep.2024.113711. Epub 2024 Jan 17. Cell Rep. 2024. PMID: 38236775 Free article. No abstract available.

5

Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses.

Aubry A, Pearson JD, Charish J, Yu T, Sivak JM, Xirodimas DP, Avet-Loiseau H, Corre J, Monnier PP, Bremner R. Aubry A, et al. Among authors: pearson jd. Cell Rep. 2023 Aug 29;42(8):112925. doi: 10.1016/j.celrep.2023.112925. Epub 2023 Aug 7. Cell Rep. 2023. PMID: 37552601 Free article.

6

Facilitating Real-Time, Multidirectional Learning for Clinicians in a Low-Evidence Pandemic Response.

Hunt RC, Braunstein SP, Cuddy Egbert L, Gorbach KA, Rao M, Pearson JD, Armistad AJ, Arora S, Bennett CA, Dezan AM, Herrmann J, Redd JT, Jolly BT, Krohmer JR, Struminger BB. Hunt RC, et al. Among authors: pearson jd. Disaster Med Public Health Prep. 2022 Sep 21;17:e246. doi: 10.1017/dmp.2022.182. Disaster Med Public Health Prep. 2022. PMID: 36128645

7

Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2.

Pires L, Wilson BC, Bremner R, Lang A, Larouche J, McDonald R, Pearson JD, Trcka D, Wrana J, Wu J, Whyne CM. Pires L, et al. Among authors: pearson jd. Sci Rep. 2022 Aug 24;12(1):14438. doi: 10.1038/s41598-022-18513-0. Sci Rep. 2022. PMID: 36002557 Free PMC article. Clinical Trial.

8

Multicenter international assessment of a SARS-CoV-2 RT-LAMP test for point of care clinical application.

Lu S, Duplat D, Benitez-Bolivar P, León C, Villota SD, Veloz-Villavicencio E, Arévalo V, Jaenes K, Guo Y, Cicek S, Robinson L, Peidis P, Pearson JD, Woodgett J, Mazzulli T, Ponce P, Restrepo S, González JM, Bernal A, Guevara-Suarez M, Pardee K, Cevallos VE, González C, Bremner R. Lu S, et al. Among authors: pearson jd. PLoS One. 2022 May 11;17(5):e0268340. doi: 10.1371/journal.pone.0268340. eCollection 2022. PLoS One. 2022. PMID: 35544541 Free PMC article.

9

Mapping transgene insertion sites reveals the α-Cre transgene expression in both developing retina and olfactory neurons.

Fan Y, Chen W, Wei R, Qiang W, Pearson JD, Yu T, Bremner R, Chen D. Fan Y, et al. Among authors: pearson jd. Commun Biol. 2022 May 3;5(1):411. doi: 10.1038/s42003-022-03379-9. Commun Biol. 2022. PMID: 35505181 Free PMC article.

10

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities.

Knudsen ES, Kumarasamy V, Nambiar R, Pearson JD, Vail P, Rosenheck H, Wang J, Eng K, Bremner R, Schramek D, Rubin SM, Welm AL, Witkiewicz AK. Knudsen ES, et al. Among authors: pearson jd. Cell Rep. 2022 Mar 1;38(9):110448. doi: 10.1016/j.celrep.2022.110448. Cell Rep. 2022. PMID: 35235778 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

328 results

Search Page